Rosuvastatin reloading before cardiac surgery with cardiopulmonary bypass

European Surgical Research

Volumn 50, Issue 1, 2013, Pages 1-13

  Kuhn, Elmar W ^a   Liakopoulos, Oliver J ^a   Deppe, Antje C ^a   Slottosch, Ingo ^a   Neef, Klaus ^a   Sterner Kock, Anja ^a   Madershahian, Navid ^a   Choi, Yeong H ^a   Wahlers, Thorsten ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Extracorporeal circulation; Heart; Ischemia reperfusion injury; Pigs; Statins; Surgery

Indexed keywords

BRADYKININ; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROSUVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL PIG; FEMALE; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HEART PRELOAD; HEART PROTECTION; HEART SURGERY; HEMODYNAMICS; HIGH ENERGY PHOSPHATE; LIPOPROTEIN BLOOD LEVEL; MEAN ARTERIAL PRESSURE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; TREATMENT DURATION; VASODILATATION; WESTERN BLOTTING; ANIMAL MODEL; ANIMAL TISSUE; EXTRACORPOREAL CIRCULATION; PIG; PREOPERATIVE PERIOD; PRESSURE VOLUME CURVE;

ANIMALS; BLOTTING, WESTERN; CARDIOPULMONARY BYPASS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROBENZENES; HEART; HEMODYNAMICS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MYOCARDIUM; PHOSPHATES; POLYMERASE CHAIN REACTION; PREOPERATIVE CARE; PYRIMIDINES; SULFONAMIDES; SWINE;

EID: 84873585491     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000345448     Document Type: Article

References (33)

1. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ: Statins and cardioprotection - more than just lipid lowering? Pharmacol Ther 2009; 122: 30-43.
2. Werner N, Nickenig G, Laufs U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-116.
3. Vilahur G, Casani L, Pena E, Duran X, Juan-Babot O, Badimon L: Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 2009; 206: 95-101.
4. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-515.
5. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
6. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
7. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, Erbel R: Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-2183.
8. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T: Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 2008; 29: 1548-1559.
9. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F: Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008; 136: 1541-1548.
10. Thielmann M, Neuhauser M, Marr A, Jaeger BR, Wendt D, Schuetze B, Kamler M, Massoudy P, Erbel R, Jakob H: Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 134: 1143-1149.
11. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340-e437.
12. Mensah K, Mocanu MM, Yellon DM: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005; 45: 1287-1291.
13. Schulz R: Pleiotropic effects of statins: acutely good, but chronically bad? J Am Coll Cardiol 2005; 45: 1292- 1294.
14. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH: The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004; 37: 449-471.
15. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDARECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54: 558-565.
16. Ellis SG, Anwaruddin S: Recapturing the magic: revisiting the pleiotropic effects of statins in percutaneous coronary revascularization. J Am Coll Cardiol 2009; 54: 566-568.
17. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003; 25: 2553-2563.
18. Klass O, Fischer UM, Perez E, Easo J, Bosse M, Fischer JH, Tossios P, Mehlhorn U: Effect of the Na+/H+ exchange inhibitor eniporide on cardiac performance and myocardial high energy phosphates in pigs subjected to cardioplegic arrest. Ann Thorac Surg 2004; 77: 658-663.
19. Lazar HL, Bao Y, Zhang Y, Bernard SA: Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 2003; 125: 1037-1042.
20. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R: Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005; 66: 462-471.
21. Ichihara K, Satoh K, Abiko Y: Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J Cardiovasc Pharmacol 1993; 22: 852-856.
22. Satoh K, Takaguri A, Itagaki M, Kano S, Ichihara K: Effects of rosuvastatin and pitavastatin on ischemiainduced myocardial stunning in dogs. J Pharmacol Sci 2008; 106: 593-599.
23. Keyes KT, Xu J, Long B, Zhang C, Hu Z, Ye Y: Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol Heart Circ Physiol 2010; 298:H1198- H1208.
24. Mocanu MM, Yellon DM: PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol 2007; 150: 833-838.
25. Parajuli N, Yuan Y, Zheng X, Bedja D, Cai ZP: Phosphatase PTEN is critically involved in post-myocardial infarction remodeling through the Akt/interleukin-10 signaling pathway. Basic Res Cardiol 2012; 107: 248.
26. Siddall HK, Warrell CE, Yellon DM, Mocanu MM: Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol 2008; 103: 560-568.
27. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S: Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45: 147-154.
28. Malik S, Sharma AK, Bharti S, Nepal S, Bhatia J, Nag TC, Narang R, Arya DS: In vivo cardioprotection by pitavastatin from ischemic-reperfusion injury through suppression of IKK/NF-kappaB and upregulation of pAkt-e-NOS. J Cardiovasc Pharmacol 2011; 58: 199-206.
29. Heusch G, Musiolik J, Gedik N, Skyschally A: Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011; 109: 1302-1308.
30. Xu H, Yang YJ, Qian HY, Tang YD, Wang H, Zhang Q: Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ J 2011; 75: 1476-1485.
31. Liakopoulos OJ, Schmitto JD, Kazmaier S, Brauer A, Quintel M, Schoendube FA, Dorge H: Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg 2007; 84: 110-119.
32. Paparella D, Yau TM, Young E: Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002; 21: 232-244.
33. Ludman AJ, Hausenloy DJ, Babu G, Hasleton J, Venugopal V, Boston-Griffiths E, Yap J, Lawrence D, Hayward M, Kolvekar S, Bognolo G, Rees P, Yellon DM: Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Res Cardiol 2011; 106: 1387-1395.